What is Capricor Therapeutics's interest coverage?

Capricor Therapeutics (CAPR) reported interest coverage of -35.5× in Q4 2025.

What does interest coverage mean?

Trailing-twelve-month operating income (EBIT) divided by interest expense. Measures how many times over the company can cover its interest payments from operating profit.

Capricor Therapeutics CAPR Interest coverage

Interest coverage at other companies

VericelVCEL

24.8×+21.4×

Dyne Therapeutics, Inc.DYN

-45.3×—

Viridian Therapeutics, Inc.VRDN

-49.3×-20.0×

LeMaitre VascularLMAT

14.1×-21.4×

MannkindMNKD

9.3×+5.2×

CytokineticsCYTK

-12.5×-1.4×

Other financials

Income statement

See full

Revenue--100%

Operating income-$36.8M-47.2%

Net income-$33.9M-39.2%

EPS (diluted)-$0.59-11.3%

Balance sheet

See full

Cash & equivalents$105.4M+266%

Total debt$14.8M+1,083%

Total equity$278.7M+118%

Total assets$326.3M+112%

Cash flow

See full

Operating cash flow-$29.3M-355%

CapEx$5.1M+472%

Free cash flow-$34.4M-369%

Valuation

See full

Market cap$1.71B+303%

Profitability

See full

Operating margin-778.8%-1,038pp

Net margin-736.6%-981pp

FCF margin-563.9%-954pp

Returns & leverage

See full

Return on equity-56.4%-11.3pp

Debt / equity0.1×0.0×

Current ratio8.4×+1.9×

Where this comes from

Calculated from Capricor Therapeutics’s reported figures.

ebit/interest expense=-35.5×

Based on trailing twelve months.

The official record: Capricor Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Capricor Therapeutics's interest coverage.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Capricor Therapeutics's interest coverage?: Capricor Therapeutics (CAPR) reported interest coverage of -35.5× in Q4 2025.
What does interest coverage mean?: Trailing-twelve-month operating income (EBIT) divided by interest expense. Measures how many times over the company can cover its interest payments from operating profit.